ANKK1/DRD2 Locus variants are associated with Rimonabant efficacy in aiding smoking cessation: Pilot data

Journal of Investigative Medicine

Volumn 59, Issue 8, 2011, Pages 1280-1283

  Wilcox, Charles S ^a   Noble, Ernest P ^b   Oskooilar, Nader ^a  

^a Pharmacology Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Consumptive disorders; DRD2 gene; Pharmacogenomics; Smoking cessation

Indexed keywords

CARBON MONOXIDE; DOPAMINE 2 RECEPTOR; PLACEBO; RIMONABANT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRD2 GENE; DRUG EFFICACY; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; SMOKING CESSATION;

CARBON MONOXIDE; GENETIC LOCI; HUMANS; PILOT PROJECTS; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RECEPTORS, DOPAMINE D2; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84856761282     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31823581fa     Document Type: Article

References (38)

1. Manual of Policies and Procedures, Center for Drug Evaluation and Research, Office of the Director, Management of the Interdisciplinary Pharmacogenomics Review Group (IPRG). Originator: Office of Clinical Pharmacology and Biopharmaceutics, 2005.
2. Pharmacogenomics: On the Road to ''Personalized Medicine.'' FDA Consumer Magazine. 2005;1-2.
3. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet. 2003;116B:103-125. (Pubitemid 37063624)
4. Grandy DK, Zhang Y, Cirelli O. PCR detection of the Taq A RFLP at the DRD2 Locus. Hum Mol Genet. 1993;2:2197. (Pubitemid 24003431)
5. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1 a novel Kinase gene linked to DRD2 on chromosome band 11q 23.1. Hum Mut. 2004;23:540-545. (Pubitemid 38720604)
6. Noble EP, Blum K, Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with receptor binding characteristics. Arch Gen Psychiatry. 1991;48:648-654.
7. Pohjalainen T, Rinne JO, Nägren K, et al. Sex difference in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry. 1998;155:768-773. (Pubitemid 28252655)
8. Noble EP, St. Jeor ST, Ritchie T, et al. D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses. 1994;42(4):257-260.
9. Comings DE, Ferry L, Bradshaw-Robinson S, et al. The dopamine D2 (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics. 1996;6(1):73-79. (Pubitemid 26096751)
10. Conner JP, Young RM, Lawford BR, et al. Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism. Addict Behav. 2007;32(2):310-319. (Pubitemid 44932206)
11. De Ruyck K, Nackaerts K, Beels L, et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics. 2010;11(8):1053-1063.
12. Zuo Y, Gilbert DG, Rabinovich NE, et al. DRD2-related Taq1A polymorphism modulates motivation to smoke. Nicotine Tob Res. 2009;11(11):1321-1329.
13. Breitling LP, Twardella D, Hoffman MM, et al. Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics. 2010;11(4):527-536.
14. FDA Clinical Briefing Document, EMDAC, NDA 200063, Contrave\ (naltrexone HCl and bupropion HCl) Extended-Release Tablets, pages 1-258.
15. Wilcox CS, Oskooilar N, Erickson JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav. 2010;25:229-234.
16. Larson C. FDA rejects diet pill contrave. FDA Examiner.com. 2011;1-3.
17. Freire MTMV, Marques FZC, Hutz MH, et al. Polymorphisms in the DBH and DRD2 gene regions and smoking behavior. Eur Arch Psychiatry Clin Neurosci. 2006;256:93-97.
18. Munafo MR, Timpson NJ, David SP, et al. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res. 2009.
19. David SP, Strong DR, Munafo MR, et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pool data from two clinical trials. Nicotine Tob Res. 2009;9(12):1241-1257.
20. Bedfont Scientific LTD., 105 Laker Road, Rochester Airport Industrial Estate, Rochester, Kent ME1, 3QX England.
21. ClinicalTrials.gov Identifier NCT00836199, NicVAX/Placebo as an Aid for Smoking Cessation. Posted February 3, 2009, updated June 10, 2011. Nabi Biopharmaceuticals and National Institute on Drug Abuse (NIDA).
22. ClinicalTrials.gov Identifier NCT01102114, NicVAX/Placebo as an Aid for Smoking Cessation. Posted March 17, 2010, updated November 9, 2010. Nabi Biopharmaceuticals and GlaxoSmithKline.
23. Chiu YH, Spiegelman D, Dockery DW, et al. Secondhand smoke exposure and inflammatory markers in non-smokers in the trucking industry. Environ Health Perspect. 2011;119(9):1294-1300.
24. Matt GE, Quintana PJ, Destaillats H, et al. Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda. Environ Health Perspect. 2011;119(9):1218-1226.
25. Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in KIF6 with MI and CHD in 2 prospective trials. J Am Coll Cardiol. 2008;51(4):435-443.
26. Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after ACS. Results from the PROVE IT-TIMI22 Study. J Am Coll Cardiol. 2008;51(4):449-455.
27. Shiffman D, Chasman DI, Ballantyne CM, et al. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the atherosclerosis risk in communities (ARIC) Study. Thromb Haemost. 2009;102:179-180.
28. Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371-376.
29. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491-1493. (Pubitemid 46906618)
30. Glenn E, Palomaki BS, Melillo S, et al. Association between 9p21 genomic markers and heart disease. JAMA. 2010;303(7):648-656.
31. Mega JL, Close S, Wiviott S, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
32. Ibeanu GC, Blaisdell J, Ghanayem BI, et al. An additional defective allele, CYP2C19 5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 1998;8(2):129-135. (Pubitemid 28227321)
33. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291(23):2847-2850. (Pubitemid 38747805)
34. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89(6):2522-2525. (Pubitemid 38766327)
35. Cigarette smoking-attributable mortality and years of potential life lost. MMWR Morbidity and Mortality Weekly Report. 1993;42:645-649.
36. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-2211.
37. Lobstein T, Millstone E. PorGrow Research Team. Context for the PorGrow study: Europe's obesity crisis. Obes Rev. 2007;8(suppl 2):7-16. (Pubitemid 46437212)
38. U.S. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Bureau. Child Health USA 2008-2009. Rockville Maryland: U.S. Department of Health and Human Services; 2009:46.